The chief of the Movement Disorders Division at Yale School of Medicine discusses the nuance around patient choice in Huntington disease testing and providing treatment regardless of confirmation. [WATCH TIME: 3 minutes]
Veronica Santini, MD, MA
Advertisement
Associate Professor of Neurology, Clinical Chief of the Movement Disorders Division, and Chief of the Comprehensive Parkinson's Disease Program, Yale School of Medicine
Articles by Veronica Santini, MD, MA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Phase 1b Interim Data on GT-02287 in Parkinson Disease: Jonas Hannestad, MD, PhD
2
Risvodetinib Demonstrates Potential Functional Benefit in Early Parkinson Disease
3
Real-World EU Data Suggest Safety of High-Dose Apomorphine Infusion in Parkinson Disease
4
Targeting Parkinson Disease "Pathway Abnormalities" With GT-02287: Jonas Hannestad, MD, PhD
5
